Please login to the form below

telaprevir

This page shows the latest telaprevir news and features for those working in and with pharma, biotech and healthcare.

2015's 'premium' prices dissuaded J&J from acquisitions, says Gorsky

to $8.1bn despite heavy competition to hepatitis C therapies Olysio (simeprevir) and Incivo (telaprevir) from Gilead and AbbVie.

Latest news

Access to new hep C treatments put under the spotlight

telaprevir). But NICE has not recommended the use of Daklinza-based regimens to treat patients with genotype 3 of the disease - which accounts for around 45% of all cases in England,
FDA approves four new medicines across multiple areas

and Vertex' Incivek (telaprevir).
J&J starts to feel biosimilar competition bite

its toll on J&J's Olysio (simeprevir) and Incivek (telaprevir) products.
Top biotech firms saw sales jump in 2014

Dion added: “ This drop was largely attributable to sliding sales of Incivek (telaprevir), Vertex's hepatitis C virus protease inhibitor, which fell by $442.3m compared with 2013, primarily as a
The end of hepatitis C?

The launch a few years ago of first-generation protease inhibitors to the pharmaco-therapeutic arsenal - Vertex' Incivek (telaprevir) and Merck &Co's Victrelis (boceprevir) - drastically improved success rates in some ... Merck &Co. III. paritaprevir.

More from news
Approximately 2 fully matching, plus 47 partially matching documents found.

Latest Intelligence

Deal Watch table for November 2013

172. Vertex / Janssen. Royalty sale. Sale of product royalty rights relating to INCIVO (telaprevir) to Janssen Pharmaceutica.
Interview: Cesar Rodriguez, Janssen

Rodriguez also references infectious diseases as a stronghold for the company, mentioning the victory for hepatitis C treatment telaprevir in the 2012 UK Prix Galien Innovative Product Award.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Scientific Team Lead: Competitive Salary

Scientific Director: Highly Competitive Salary &Benefits

Associate Medical Director: Salary TBC

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Account Director - Digital: Great salary and benefits

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Experienced Editor, London, Medical Communications: Competitive package

Associate Medical Director: Highly Competitive

Director – Head of Public Affairs: Neg

Senior Account Executive – Medical Communications: Salary TBC

Account Director: Negotiable

Director Healthcare PR Communications: Salary TBC

Account Director – Global Healthcare PR: Salary TBC

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Project / Account Manager (Medical Education): Salary TBC

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Senior Medical Writer (Remote Working): Competitive Salary Offered

Account Manager, Healthcare Advertising: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Editorial Director – Medical Education: Neg

Subscribe to our email news alerts

PMHub

Add my company

AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds: A vision of Paris as Europe's leading hub for life sciences innovation...